|Mr. Alan H. Auerbach||Founder, Chairman, Pres, CEO & Sec.||1.3M||N/A||1970|
|Mr. Maximo F. Nougues||CFO & Principal Accounting Officer||665.8k||N/A||1969|
|Dr. Richard P. Bryce||Chief Medical & Scientific Officer||720.3k||N/A||1957|
|Mr. Douglas Hunt||Sr. VP of Regulatory Affairs, Medical Writing & Project Management||523.83k||N/A||1965|
|Mr. Mariann Ohanesian||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Charon Spencer Sr.||VP of HR||N/A||N/A||N/A|
|Mr. Jeffrey Jerome Ludwig||Chief Commercial Officer||N/A||N/A||1966|
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. The company was founded in 2010 and is headquartered in Los Angeles, California.
Puma Biotechnology, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 3; Compensation: 8.